A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

PUR0200

Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator

DRUG

PUR0200 Placebo

Randomized, single dose of inhaled placebo matched to PUR0200

DRUG

Active comparator

Randomized single dose of inhaled active comparator product

Trial Locations (2)

M23 9QZ

Medicines Evaluation Unit, Manchester

NG11 6JS

Quotient Clinical, Nottingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Quotient Clinical

OTHER

lead

Pulmatrix Inc.

INDUSTRY

NCT01921712 - A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients | Biotech Hunter | Biotech Hunter